Dr Reddys Labs executive reports 68,230 shares

Q: Who is the reporting person on the RDY Form 3 insider filing?

The reporting person is Motupalli Venkata Ramana, identified as CEO - Global Generics at DR REDDYS LABORATORIES LTD. The filing discloses his direct beneficial ownership of 68,230 Equity Shares in the company’s stock as required for insiders.

Q: Is the ownership reported in the RDY Form 3 direct or indirect?

The ownership reported is direct. The Form 3 indicates that Motupalli Venkata Ramana holds 68,230 Equity Shares directly, rather than through an intermediary entity or indirect structure, clarifying the nature of his beneficial stake in DR REDDYS LABORATORIES LTD.

DR REDDYS LABORATORIES LTD executive Motupalli Venkata Ramana, who serves as CEO - Global Generics, has filed an initial ownership report showing direct holdings of 68,230 Equity Shares of the company.

Accepted by SEC EDGAR 04/01/2026 - 11:53 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

DR REDDYS LABORATORIES LTD executive Motupalli Venkata Ramana, who serves as CEO - Global Generics, has filed an initial ownership report showing direct holdings of 68,230 Equity Shares of the company. This Form 3 reflects his beneficial ownership position rather than a new buy or sell transaction.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider MOTUPALLI VENKATA RAMANA

Role CEO - Global Generics

Type	Security	Shares	Price	Value
Holding	Equity Shares	--	--	--

Holdings: Equity Shares — 68,230 shares (Direct)

Key Figures

Direct beneficial holdings: 68,230 Equity Shares

1 metrics

Direct beneficial holdings 68,230 Equity Shares Total shares beneficially owned following the reported holding entry

Key Terms

Equity Shares, CEO - Global Generics, direct

3 terms

Equity Shares financial

"security_title: "Equity Shares""

Equity shares are units of ownership in a company that give the holder a claim on a portion of its assets and profits, like owning a slice of a business. They matter to investors because their value can rise or fall with the company’s performance and market sentiment, may provide periodic income through dividends, and often carry voting rights that influence how the business is run.

CEO - Global Generics financial

"officer_title: "CEO - Global Generics""

direct financial

"ownership_type: "direct""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the RDY Form 3 filed by Motupalli Venkata Ramana show?

The Form 3 shows that Motupalli Venkata Ramana, CEO - Global Generics at DR REDDYS LABORATORIES LTD, directly holds 68,230 Equity Shares. This is an initial ownership disclosure, not a record of a new stock purchase or sale.

How many DR REDDYS LABORATORIES (RDY) shares does the generics CEO hold?

The CEO - Global Generics, Motupalli Venkata Ramana, reports direct ownership of 68,230 Equity Shares of DR REDDYS LABORATORIES LTD. This figure represents his beneficial holdings reported in the Form 3 insider ownership filing.

Does the RDY Form 3 indicate any recent insider buying or selling?

No new buying or selling is indicated. The Form 3 for Motupalli Venkata Ramana records direct beneficial ownership of 68,230 Equity Shares, serving as an initial statement of holdings rather than documenting a specific transaction in the company’s stock.

Who is the reporting person on the RDY Form 3 insider filing?

The reporting person is Motupalli Venkata Ramana, identified as CEO - Global Generics at DR REDDYS LABORATORIES LTD. The filing discloses his direct beneficial ownership of 68,230 Equity Shares in the company’s stock as required for insiders.

Is the ownership reported in the RDY Form 3 direct or indirect?

The ownership reported is direct. The Form 3 indicates that Motupalli Venkata Ramana holds 68,230 Equity Shares directly, rather than through an intermediary entity or indirect structure, clarifying the nature of his beneficial stake in DR REDDYS LABORATORIES LTD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MOTUPALLI VENKATA RAMANA

(Last)

(First)

(Middle)

PLOT NO 12, AKASH NAGAR, NEW BOWENPALLY,

BEHIND BAPUJI NAGAR

(Street)

HYDERABAD

TELANGANA

500011

(City)

(State)

(Zip)

INDIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
12/18/2025

3. Issuer Name and Ticker or Trading Symbol
DR REDDYS LABORATORIES LTD [ RDY ]

3a. Foreign Trading Symbol
[DRREDDY&500124]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO - Global Generics

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Equity Shares	68,230	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

	/s/ M V RAMANA	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR